Leprosy is curable, and for public health programmes this has often been treated as the end of the story. However, for thousands of people in East Africa who once had the disease, cure marks the beginning of a different and ongoing crisis.
After completing multidrug therapy (MDT), people are declared cured and removed from treatment registers. The infection is eliminated, and the bacteria are cleared from the body.
But nerve damage, physical disability, social exclusion, and economic loss often remain for life.
These long-term consequences affect people formerly affected by leprosy (PFAL). Their needs receive little attention in health policy, disability services, and social protection systems across the region.
Why Disability Persists Despite Declining Leprosy Cases
A person in East Africa living with lasting disability after cure from leprosy. Physical impairment often continues long after the infection has been treated, affecting daily life.
What is leprosy?
Leprosy, also known as Hansen disease, is a chronic infectious disease caused by the bacterium Mycobacterium leprae. The disease primarily affects the skin and peripheral nerves, which are the nerves outside the brain and spinal cord. If untreated, leprosy can lead to progressive nerve damage, resulting in loss of sensation, muscle weakness, and permanent disability.
Causes and Transmission
Leprosy is transmitted through prolonged close contact with an untreated infected person, mainly via respiratory droplets. The disease has a long incubation period, often ranging from two to five years or longer. Not everyone exposed to Mycobacterium leprae develops leprosy. Epidemiological evidence shows that the vast majority of people, estimated at more than 95 percent of the global population, have natural immunity to the bacterium and do not develop clinical disease even after prolonged exposure.
Signs and Symptoms
Early symptoms of leprosy may be mild and are often overlooked. Common clinical features include:
- Pale or reddish skin patches with reduced sensation
- Numbness or tingling in the hands and feet
- Thickened or enlarged peripheral nerves
- Muscle weakness, particularly in the hands, feet, or face
As the disease progresses, nerve damage can lead to injuries that go unnoticed, repeated infections, chronic ulcers, and visible deformities of the hands, feet, and eyes.
Diagnosis
Leprosy is diagnosed through clinical examination, focusing on skin lesions and nerve involvement. Laboratory confirmation may involve skin smears or biopsies to detect Mycobacterium leprae. Early diagnosis is critical, as timely treatment can prevent nerve damage and long-term disability.
Treatment
Leprosy is treated using multidrug therapy (MDT), which combines antibiotics such as rifampicin, dapsone, and clofazimine. MDT is highly effective and cures the infection when taken for the recommended duration. Treatment is provided free of charge through programmes supported by the World Health Organization. Once a person completes MDT, they are no longer infectious and cannot transmit the disease to others.
However, MDT does not reverse nerve damage that has already occurred. As a result, many individuals continue to experience disability even after being medically cured.
(World Health Organization, Regional Office for Africa, 2023)
Trends in Leprosy Transmission and Disability in East Africa
Reported leprosy cases in the African Region have declined over the past two decades. In 2000, more than 57,000 new cases were reported. By 2010, this number had fallen to about 34,000.
(World Health Organization, Regional Office for Africa, 2023)
Most East African countries, including Kenya, Uganda, Tanzania, Rwanda, and Ethiopia, achieved the World Health Organization target of eliminating leprosy as a public health problem by the early 2000s. Elimination is defined as a registered prevalence of fewer than one case per 10,000 population at national level.
This indicator measures infection alone and therefore does not account for disability, stigma, or long-term harm.
While global estimates suggest that more than one million people live with disabilities caused by past leprosy, a substantial proportion of this population is concentrated in Africa. In East Africa, national programme data and research studies indicate that tens of thousands of people live with leprosy-related disability, particularly in Ethiopia, Tanzania, and Kenya.
Ethiopia alone reports one of the highest burdens of leprosy-related disability in Africa, with studies showing that approximately one-third of newly diagnosed patients already present with visible disability at the time of diagnosis. In Kenya, research from coastal counties such as Kwale and Kilifi indicates a persistent population of people living with established nerve damage and functional impairment long after completion of treatment.
These findings suggest that although transmission has declined across East Africa, the number of people living with the long-term consequences of leprosy remains significant and largely unquantified in national disability statistics.
This means that while transmission has declined, the population of PFAL remains large and largely unsupported.
Late Diagnosis Creates Lifelong Disability
Disability in leprosy is caused by damage to peripheral nerves. When nerves lose sensation, injuries go unnoticed. Burns, cuts, and pressure wounds become infected. Chronic ulcers develop. Muscle weakness leads to deformities of the hands and feet.
This damage is preventable with early diagnosis and timely MDT.
In East Africa, late diagnosis remains common.
In Ethiopia, a national analysis found that about 33 percent of newly detected leprosy patients already had visible disability at the time of diagnosis. This is called Grade 2 Disability (G2D). G2D means visible deformity or severe visual impairment.
(Tegene and Atnafu, PLOS Neglected Tropical Diseases, 2024)
In Kenya, studies from Kwale and Kilifi counties found that many patients presented late, with established nerve damage and visible impairment at the time of diagnosis.
(Karugu et al., East African Medical Journal, 2024)
These findings indicate that many people continue to seek care too late for disability to be prevented. Late presentation is driven by a combination of factors, including limited community awareness of early leprosy symptoms, persistent stigma, fear of discrimination, and weak access to primary health services in remote and underserved areas. In some settings, early skin changes are not recognised by patients or health workers, while mild sensory loss is often ignored until visible deformity develops.
Health system constraints also contribute to delay. In several East African countries, leprosy services are increasingly integrated into general health care, where frontline staff may have limited training or experience in early detection. Together, these social and health system factors result in delayed diagnosis, higher rates of nerve damage at presentation, and a growing population of people formerly affected by leprosy who live with permanent disability.
What Life After Cure Often Looks Like
For most people formerly affected by leprosy, the primary challenge after completing treatment is not ongoing infection but the long-term consequences of nerve damage. Although multidrug therapy eliminates the bacterium, it does not reverse neurological injury that has already occurred.
As a result, loss of sensation in the hands and feet is common, and this is frequently accompanied by muscle weakness and reduced grip strength. Walking may become difficult due to foot drop, chronic ulcers, or repeated injuries that go unnoticed because of sensory loss. Over time, these impairments can lead to recurrent wounds, infections, and visible deformities.
These physical limitations directly affect daily functioning. Activities such as farming, manual labour, cooking, and household work become difficult or impossible, particularly in rural settings where livelihoods depend on physical strength. As functional ability declines, many individuals become increasingly dependent on family members for basic tasks and income support.
Evidence from low- and middle-income countries consistently shows that people living with leprosy-related disability experience significant restrictions in mobility, self-care, and participation in work and community life (Van Brakel et al., 2012).
Comparative experiences across East Africa
Across East Africa, the lived experience of people formerly affected by leprosy follows similar patterns, although the availability of support services varies by country.
In Ethiopia, studies report high levels of untreated disability among people who have completed MDT, particularly in rural areas where access to rehabilitation services is limited. Many individuals continue to live with chronic ulcers and progressive deformities, despite having been medically cured years earlier.
In Kenya, research from coastal counties such as Kwale and Kilifi shows that people formerly affected by leprosy often lack access to physiotherapy, protective footwear, and consistent wound care after treatment completion. Follow-up services are minimal, and patients are rarely monitored for worsening disability once they are discharged from leprosy programmes.
In Tanzania, similar challenges have been documented, with rehabilitation services largely concentrated in referral hospitals and mission facilities. For people living far from these centres, ongoing care is difficult to access, resulting in preventable complications and functional decline.
Gaps in rehabilitation and follow-up care
Across the region, rehabilitation services remain scarce. Physiotherapy is limited, protective footwear is rarely available outside specialised centres, and assistive devices are difficult to obtain. Long-term follow-up after completion of MDT is uncommon, and disability care is often excluded from routine health services.
As a result, many people formerly affected by leprosy live for decades with preventable complications, unmanaged impairments, and declining quality of life, despite having been cured of the disease.
Stigma Does Not End With Cure
Leprosy carries deep social stigma, defined as social rejection driven by fear and misunderstanding. Even after cure, visible disability can identify a person as someone who had leprosy, which in many communities leads to ongoing discrimination.
People formerly affected report being avoided, excluded from social events, and rejected as marriage partners. They face barriers to employment and participation in community life.
A scientific review of stigma related to leprosy found strong evidence that discrimination persists long after medical cure and contributes to long-term psychological distress.
(International Textbook of Leprosy, 2022)
In 2023, the WHO Regional Office for Africa stated that stigma and discrimination remain major barriers to early diagnosis and social reintegration.
(World Health Organization, Regional Office for Africa, 2023)
Stigma worsens poverty.
Stigma reduces care-seeking.
Stigma damages mental health.
Economic Consequences for Individuals and Families
Disability and stigma combine to reduce income.
Many PFAL lose their livelihoods. Farming becomes impossible with foot ulcers or hand deformities. Employers refuse to hire people with visible impairments.
Households lose income. Children drop out of school. Health expenses rise.
Research shows that leprosy-related disability is strongly associated with long-term poverty and economic hardship.
(Van Brakel et al., PLOS Neglected Tropical Diseases, 2012)
This creates a cycle.
Poverty delays care-seeking.
Delayed care increases disability.
Disability deepens poverty.
Health Systems Stop Caring Too Early
Photo by fitra zulfy on Unsplash
Primary health care facilities in East Africa focus on diagnosis and treatment of active leprosy cases. Long-term follow-up and rehabilitation services remain limited.
Public health programmes in East Africa prioritise the detection of new leprosy cases and the completion of multidrug therapy (MDT), reflecting long-standing global targets focused on transmission reduction. Once treatment ends, however, structured follow-up and disability care often stop.
This gap is closely linked to how leprosy is financed within national health systems. Funding for leprosy falls under broader neglected tropical disease (NTD) programmes, which are heavily donor-dependent and largely oriented toward elimination targets rather than long-term care. As external funding for NTDs declines or shifts to other priorities, resources for rehabilitation, follow-up, and social support for people formerly affected by leprosy remain extremely limited.
As a result, health systems invest in curing infection but provide little support for managing the lifelong consequences of the disease.
There are few structured programmes for:
- Rehabilitation
- Long-term wound care
- Mental health support
- Economic reintegration
The WHO Global Leprosy Strategy 2021–2030 calls for a shift toward “zero disability and zero discrimination.”
(World Health Organization, 2021)
It emphasizes disability care and social inclusion.
In practice, these components remain weakly implemented.
PFAL falls outside disease programmes and outside disability programmes.
They become invisible.
This Is a Human Rights Issue
The United Nations recognizes discrimination against people affected by leprosy as a human rights violation.
In 2010, the United Nations General Assembly adopted principles to eliminate discrimination against people affected by leprosy and their families.
(United Nations General Assembly Resolution A/RES/65/215)
These principles call for equal access to education, employment, health care, and housing.
What Needs to Change
Evidence from East Africa and global leprosy policy documents points to several priority areas where current approaches fall short.
Earlier diagnosis and active case finding
Multiple studies show that late diagnosis is the main driver of leprosy-related disability. Research from Ethiopia and Kenya demonstrates that a high proportion of patients already have visible disability at diagnosis, indicating delayed care-seeking and missed opportunities for prevention. Active case finding and improved training of primary health workers are therefore essential to reducing future disability burdens.
Rehabilitation and disability care integrated into primary health care
The World Health Organization’s Global Leprosy Strategy 2021–2030 explicitly identifies rehabilitation as a core component of leprosy control. Evidence shows that access to basic physiotherapy, protective footwear, and wound care can prevent secondary complications and functional decline. Yet in most East African countries, these services remain concentrated in referral hospitals, making them inaccessible to rural populations.
Routine follow-up after completion of MDT
Studies indicate that nerve damage and reactions can continue or worsen after treatment completion. Routine post-MDT follow-up is therefore necessary to identify complications early and prevent progression of disability. However, follow-up is rarely institutionalised within national leprosy programmes.
Psychological and social support
Systematic reviews have documented high levels of depression, anxiety, and social isolation among people affected by leprosy, even years after cure. Addressing stigma and mental health requires structured psychosocial support, which is largely absent from current service models.
Economic inclusion and social protection
Evidence consistently links leprosy-related disability with long-term poverty. Skills training, livelihood support, and inclusion in social protection programmes have been shown to improve quality of life and economic independence but are rarely targeted toward people formerly affected by leprosy.
Legal protection against discrimination
The United Nations has recognised discrimination against people affected by leprosy as a human rights violation. Enforcement of anti-discrimination laws is necessary to address persistent exclusion from employment, education, and social life.
Conclusion
Leprosy is curable, but cure alone does not restore health, dignity, or economic security.
Across East Africa, people formerly affected by leprosy continue to live with preventable disability, persistent stigma, and long-term poverty decades after completing treatment. While public health programmes have successfully reduced transmission, they have largely failed to address the lasting damage caused by the disease.
Disability care, social inclusion, and human rights protections remain peripheral rather than central to leprosy control efforts. Until these elements are integrated into health and social systems, cure will remain incomplete.
The lives of people formerly affected by leprosy are not a legacy issue from the past. They reflect ongoing gaps in health policy, financing, and social protection in the present.
References
- World Health Organization, Regional Office for Africa. Leprosy Fact Sheet. 2023.
https://www.afro.who.int/health-topics/leprosy - World Health Organization. Global Leprosy Strategy 2021–2030: Towards Zero Leprosy.
https://www.who.int/publications/i/item/9789240028500 - Tegene BA, Atnafu TA. Relevance of reporting leprosy-related disability at completion of multidrug therapy.
PLOS Neglected Tropical Diseases, 2024.
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0012720 - Karugu M et al. Assessment of disability among leprosy patients on treatment initiation in Kwale and Kilifi counties, Kenya.
East African Medical Journal, 2024. - Van Brakel WH et al. Disability in people affected by leprosy.
PLOS Neglected Tropical Diseases, 2012.
https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0001686 - United Nations General Assembly. Resolution A/RES/65/215. 2010.
https://undocs.org/A/RES/65/215 - International Textbook of Leprosy. Stigma Related to Leprosy: A Scientific View. 2022.
https://internationaltextbookofleprosy.com
About the Author
